

**Zoono Group Limited (ASX: ZNO)
ASX ANNOUNCEMENT**

5 August 2025

Rights Issue Closure and Shortfall Notification

Zoono Group Limited (**Company**) (ASX: ZNO) is pleased to advise that its recent non-renounceable rights issue on the basis of one (1) new Share for every seven (7) existing Shares held by each Eligible Shareholder on the Record Date at an issue price of \$0.035 per Share (**Offer**) has now closed, raising \$785,005.55 (NZ\$859,432) before costs.

The results of the Offer are as follows:

	Shares
Total number offered	50,777,949
Total number applied for	22,428,730
Remaining Shortfall number (Shortfall Offer)	28,349,219

All Directors all took up their full entitlements under the Offer, with the Managing Director and largest shareholder, Paul Hyslop, subscribing for 14,921,072 New Shares. The Managing Director, Paul Hyslop is also able to provide more support to the Company in the form of a loan if required.

Entitlements not taken up pursuant to the Offer form the Shortfall Offer. The Shortfall Offer is a separate offer made pursuant to the Offer Document and will remain open for up to three months following the Closing Date. The issue price for each Share issued under the Shortfall Offer is \$0.035, being the price at which Shares were offered under the Offer.

Funds raised from the issue funds from the Rights Issue will be used for the supermarket shelf-life extension project, China and India expansion, repayment of related party debt, patents and IP protection, working capital and expenses of the Offer.

Zoono will issue and allot a total of 22,428,730 New Shares pursuant to the Offer today.

This announcement has been authorised and approved for release to ASX by the Board of Zoono Group Limited.

For personal use only

For further information, please contact:

Zoono Group Limited

Paul Hyslop
Group MD
M: +64 21 659 977
E: paul.hyslop@zoono.com

Paul Ravlich
Group CFO
M: +64 21 075 9176
E: paul.ravlich@zoono.com

About Zoono

Zoono Group Limited is a global biotech company that develops, manufactures and distributes a suite of scientifically validated, long-lasting and environmentally-friendly antimicrobial solutions. Zoono's mission is to improve health and well-being through innovative, safe, non-toxic and durable germ protection.

Zoono produces sprays, wipes and foams suited for skin care, surface sanitisers, and mould remediation treatments. The products are based on the 'zoono molecule', a unique antimicrobial molecule that bonds to any surface and kills pathogens including bacteria, viruses, algae, fungi and mould.

Zoono's products have received numerous regulatory approvals and the company's technology claims are supported by independent testing conducted in laboratories worldwide. Zoono is headquartered in New Zealand and its products are available globally.

To learn more, please visit: www.zoono.com

For personal use only